RTTNews BiotechQwen · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 17:15:17·⟳ 抓取 17:30:18 +15m01s·⚡ 决策 09-14 17:36:17 +5m59s·43.2 天前
阿斯利康（AZN.US）Tagrisso在ADAURA III期公布8年总生存随访（II-IIIA期HR 0.53、8年OS 74% vs 58%），属已获批辅助标准治疗的探索性长随访，对2484亿美元市值无增量业绩信息
事件为已获批、已被认定标准治疗的ADAURA试验8年探索性OS随访，临床意义重大但不构成新的状态迁移（无新适应症、无新审批、无指引或峰值销售变化）；卖方一致预期早已包含Tagrisso辅助地位，对2484亿美元市值的增量弹性无法量化；跨市场二阶映射（国产三代EGFR-TKI、EGFR检测）只有品类主题联动、无真实权益或订单敞口，故全部候选AVOID
📄 原文RTTNews Biotech↗ 原文
AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 AstraZeneca（美股ADR）（AZN.US）
超大市值（约2484亿美元）主标的的确认性软催化：ADAURA的OS获益此前已阳性、Tagrisso辅助适应症早已获批并被卖方视为标准治疗，本次8年随访无新增收入、审批、标签或指引事实，无法写出可交易窗口内的业绩增量；盘前+0.68%发生在3,638股的无量环境中，不构成有效重定价，且13周轨迹下行（100→90）、距52周高-23.4%，做多逆风。自家案例库亦显示AZN软催化ENTER胜率极低
不做 艾力斯（688578.SH）
无因果敞口：伏美替尼的辅助治疗价值取决于自身试验进度、获批与医保放量，AZN的ADAURA长随访只是品类既有认知的再确认，无法量化出新增患者数×价格×权益的增量，属第五层主题beta，不写成业绩受益
不做 翰森制药（03692.HK）
无因果敞口：阿美替尼为国产三代EGFR-TKI大单品，本事件不含与其权益、审批或订单相关的任何新增事实，仅同品类情绪联动，不足以支撑方向性交易
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Tagrisso辅助治疗8年OS随访是临床层面的巩固性证据，而非新增商业事实：该适应症早已获批并被内部研报确认为EGFR+ NSCLC在位标准，卖方预测与公司汇编一致预期相符。主标的市值2484亿美元、盘前仅3,638股成交的+0.68%不具交易含义，二阶国产竞品也拿不出可量化的权益增量，故不做。
🔎 新鲜度:最早出现 2026-09-14 · 扩散 low · price-in 风险 high ↗
消息传播链
- 本臂可见最早节点，转述IASLC 2026 WCLC上ADAURA探索性OS更新并引用PI Roy Herbst与AZN肿瘤研发EVP Susan Galbraith的表述；因web_search多次返回无关结果，未能定位AZN newsroom/IASLC摘要原文，故首发时间与官方措辞标注为未核验市场反应:AZN.US盘前05:25 ET报161.26美元（+0.68%），盘前成交仅3,638股、额58.6万美元，属无量漂移，不构成有效重定价
- 2026-09-14 05:25 ET市场反应futu行情（stock_quote）非一手事件后主标的无放量、无异动，与'确认性数据已被预期'一致；周五收160.17美元，近5日-2.79%、13周指数化轨迹自100降至90市场反应:prev_close 159.64 → 收盘160.17（+0.33%），盘前161.26（+0.68%）
关键理由
- ADAURA的关键次要终点OS此前已阳性、Tagrisso辅助适应症已获批并被卖方视为EGFR+ NSCLC稳固在位品种（高盛2026-05 IQVIA分析、摩根大通/高盛2026-08研报），8年随访只是延长已知获益曲线，不改变2026-30年销售预测
- 对2484亿美元市值、PE 24.5、13周轨迹由100跌至90、距52周高-23.4%的主标的，无金额增量的会议数据不构成可交易窗口内改变收入/利润/capex指引的硬催化
主要风险
- 若WCLC原文另含标签扩展、新增注册性数据或公司上调Tagrisso峰值销售，materiality需重估；本轮web_search通道降级未能核验AZN官方原文
- AZN近期存在并购传闻等其它催化（内部库2026-08复盘提及洽购百时美）及2天后FOMC决议，可能主导短期股价，与本事件无关
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-05-29 · 影响 weakens
内部研报确认Tagrisso已稳固在位、份额动态稳定、预测与一致预期相符，长随访不产生新增销售弹性
检索:Tagrisso 竞争格局 Rybrevant 处方份额 一致预期（kb_search：AstraZeneca Tagrisso osimertinib ADAURA adjuvant sales forecast） 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-09-08 · 影响 weakens
AZN.US相关历史决策145条、其中ENTER仅1条（0.7%），该笔T+1开盘→出场开盘-0.58%；近月多条AZN软催化（tozorakimab旧闻再传播、Etcamah获批等）均判不做，校准结论为超大市值药企软催化不交易
检索:search_case_library(AZN.US)：我们过去在阿斯利康上的同类催化决策与次日表现 - 做多前查反向 · 来源 kb_search · 日期 2026-08-04 · 影响 none
命中国联民生医药艾力斯专题纪要，内容为国产三代EGFR-TKI迭代史与单品放量逻辑（奥希替尼为基准、阿美替尼约60亿单品），未见任何将AZN随访数据映射为国产竞品收入增量的证据
检索:国产三代EGFR-TKI 伏美替尼/阿美替尼 术后辅助 是否受ADAURA数据驱动（kb_search）
先例如何影响了这次决策
对本次决策的影响:先例缺失未改变结论：AVOID的依据是materiality与无增量事实（超大市值+已获批已预期），而非价格幅度校准
方向:无可用外部先例面板；仅能依据内部研报口径与自家决策史判断此类超大市值药企的确认性会议数据通常不产生可交易的方向性重定价
涨幅量级:未取到高相似、锚干净的aligned样本，无法用先例校准tp/sl幅度——本次也未给出任何ENTER，故不需要幅度参数
形态:无先例可判断见光死/高开低走；本轮观察到的盘前+0.68%发生在3,638股的无量环境中，不能视为真实反应
工具执行结果 · 成功 16 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 20 ms
{"result": "search_processed_events:agent query=`astrazeneca tagrisso 8-year overall survival adaura | azn tagrisso eight-year landmark survival early-stage lung cancer | osimertinib adjuvant egfr-mutated nsclc iaslc wclc 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent q - fetch_decision_experience 成功 stock_tools HTTP · 18 ms
{ - web_search 成功 Bing RSS · 275 ms
Bing RSS 搜索结果（原始查询:ADAURA overall survival results osimertinib previously reported 2023 ESMO NEJM early-stage EGFR NSCLC） - web_search 成功 Bing RSS · 250 ms
Bing RSS 搜索结果（原始查询:Tagrisso sales 2025 AstraZeneca revenue guidance adjuvant market share） - stock_quote 成功 stock_tools HTTP · 280 ms
{ - kb_search 降级 stock_tools HTTP · 5,157 ms
{ - web_search 成功 Bing RSS · 246 ms
Bing RSS 搜索结果（原始查询:ADAURA osimertinib overall survival 8-year update WCLC 2026） - web_search 成功 Bing RSS · 280 ms
Bing RSS 搜索结果（原始查询:Tagrisso annual sales AstraZeneca billion） - kb_search 成功 stock_tools HTTP · 3,529 ms
{ - web_search 成功 Bing RSS · 492 ms
Bing RSS 搜索结果（原始查询:艾力斯 伏美替尼 术后辅助治疗 适应症 EGFR 2026） - kb_fetch_document 成功 stock_tools HTTP · 40 ms
{ - web_search 成功 Bing RSS · 257 ms
Bing RSS 搜索结果（原始查询:"osimertinib" ADAURA "overall survival" 2023 hazard ratio five-year） - kb_search 成功 stock_tools HTTP · 2,307 ms
{ - web_search 成功 Bing RSS · 529 ms
Bing RSS 搜索结果（原始查询:AstraZeneca ADAURA overall survival results announced Tagrisso adjuvant approval） - search_case_library 成功 stock_tools HTTP · 54 ms
{"result": "search_case_library「AZN.US」—— 与这些标的相关的自家决策案例(本页 10 条,该标的全历史相关记录共 145 条；ENTER 只按该标的自己的腿统计):\n◆ AZN.US：相关历史决策 145 条 · 其中该标的 ENTER 1 条(0.7%) · 已结算 1 笔 · 胜率 0% · 中位 -0.58% · 均值 -0.58% ⚠️只有 1 笔,样本太薄,只能当线索不能当规律\n↑ 胜率/收益口径:ENTER 当日之后 T+1 开盘入场、次日开盘出场,做空腿已按方向取反(所以正数=这个方向做对了)。统计的只有★那只票自己的腿。\n【对所查标 - normalize_ticker 成功 stock_tools HTTP · 46 ms
{ - normalize_ticker 成功 stock_tools HTTP · 16 ms
{
原文全文
展开原文 · 9,643 字
AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer
By
TajSabreen Ahamed
✉
Published:
9/14/2026 5:15 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
AstraZeneca's (
AZN
) TAGRISSO (osimertinib) delivered an unprecedented eight-year landmark overall survival benefit in early-stage EGFR-mutated non-small cell lung cancer (NSCLC), marking the longest survival ever reported in a global Phase III trial in this setting.
TAGRISSO demonstrated a sustained and clinically meaningful overall survival advantage compared with placebo in the ADAURA Phase III trial, which evaluated adjuvant treatment in patients with resected early-stage EGFR-mutated NSCLC (Stages IB-IIIA) following complete tumor removal with curative intent.
Patients treated with TAGRISSO showed a 47% reduction in risk of death in the primary population (Stages II-IIIA) (HR 0.53; 95% CI 0.38-0.75) and a 48% reduction in the overall trial population (Stages IB-IIIA) (HR 0.52; 95% CI 0.39-0.71). At eight years, 74% of TAGRISSO-treated patients in the primary population were alive versus 58% on placebo, and 79% versus 64% in the overall population, reinforcing the durability of benefit across all predefined subgroups.
Roy S. Herbst, MD, PhD, principal investigator of ADAURA, noted that patients continue to experience meaningful long-term benefit with adjuvant osimertinib, highlighting a 16-percentage-point improvement in overall survival at eight years despite high crossover rates to TAGRISSO after recurrence. He emphasized the importance of EGFR testing at diagnosis to ensure eligible patients can access this therapy.
Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, stated that ADAURA continues to set new benchmarks in early-stage EGFR-mutated lung cancer, with nearly 80% of patients alive at eight years, reinforcing TAGRISSO as the adjuvant standard of care and backbone therapy across disease stages.
About the ADAURA Phase III Trial
ADAURA is a global, randomized, double-blind Phase III study evaluating TAGRISSO versus placebo in patients with completely resected early-stage EGFR-mutated NSCLC. The trial's primary endpoint was disease-free survival, with overall survival as a key secondary endpoint. Updated exploratory OS results presented at the IASLC 2026 World Conference on Lung Cancer further strengthen TAGRISSO's role in early-stage treatment strategy.
AZN has traded between $145.80 and $212.71 over the past year. The stock closed Friday's trading (September 11, 2026) at $160.17, up 0.33%. In pre-market trading the stock is at $161.69, up 0.96%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
AstraZeneca's Enhertu Improves PFS By 6 Months In First-Line HER2-Mutant NSCLC; Daiichi Stock Up
AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective
AstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPD
AstraZeneca's Etcamah Approved In U.S. For 1st-Line Advanced HR-Positive Breast Cancer
AstraZeneca Announces Approval Of Etcamah Combination In The US
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer
By
TajSabreen Ahamed
✉
Published:
9/14/2026 5:15 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
AstraZeneca's (
AZN
) TAGRISSO (osimertinib) delivered an unprecedented eight-year landmark overall survival benefit in early-stage EGFR-mutated non-small cell lung cancer (NSCLC), marking the longest survival ever reported in a global Phase III trial in this setting.
TAGRISSO demonstrated a sustained and clinically meaningful overall survival advantage compared with placebo in the ADAURA Phase III trial, which evaluated adjuvant treatment in patients with resected early-stage EGFR-mutated NSCLC (Stages IB-IIIA) following complete tumor removal with curative intent.
Patients treated with TAGRISSO showed a 47% reduction in risk of death in the primary population (Stages II-IIIA) (HR 0.53; 95% CI 0.38-0.75) and a 48% reduction in the overall trial population (Stages IB-IIIA) (HR 0.52; 95% CI 0.39-0.71). At eight years, 74% of TAGRISSO-treated patients in the primary population were alive versus 58% on placebo, and 79% versus 64% in the overall population, reinforcing the durability of benefit across all predefined subgroups.
Roy S. Herbst, MD, PhD, principal investigator of ADAURA, noted that patients continue to experience meaningful long-term benefit with adjuvant osimertinib, highlighting a 16-percentage-point improvement in overall survival at eight years despite high crossover rates to TAGRISSO after recurrence. He emphasized the importance of EGFR testing at diagnosis to ensure eligible patients can access this therapy.
Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, stated that ADAURA continues to set new benchmarks in early-stage EGFR-mutated lung cancer, with nearly 80% of patients alive at eight years, reinforcing TAGRISSO as the adjuvant standard of care and backbone therapy across disease stages.
About the ADAURA Phase III Trial
ADAURA is a global, randomized, double-blind Phase III study evaluating TAGRISSO versus placebo in patients with completely resected early-stage EGFR-mutated NSCLC. The trial's primary endpoint was disease-free survival, with overall survival as a key secondary endpoint. Updated exploratory OS results presented at the IASLC 2026 World Conference on Lung Cancer further strengthen TAGRISSO's role in early-stage treatment strategy.
AZN has traded between $145.80 and $212.71 over the past year. The stock closed Friday's trading (September 11, 2026) at $160.17, up 0.33%. In pre-market trading the stock is at $161.69, up 0.96%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
AstraZeneca's Enhertu Improves PFS By 6 Months In First-Line HER2-Mutant NSCLC; Daiichi Stock Up
AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective
AstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPD
AstraZeneca's Etcamah Approved In U.S. For 1st-Line Advanced HR-Positive Breast Cancer
AstraZeneca Announces Approval Of Etcamah Combination In The US
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。